| CEO: | Adrian Kinkaid |
| Chairman: | Simon Gordon Douglas |
| Chief Scientific Officer: | Richard John Buick |
| Non-Executive Dir: | Colin Walsh, Matthew Baker |
| Address: | Springbank Industrial Estate, 1 Springbank Rd, Dunmurry, Belfast, United Kingdom, BT17 0QL |
| Website: | https://www.fusionantibodies.com/ |
| Sector: | Health Care(LSE) |
| Index: | FTSE AIM All-Share |
| ISIN: | GB00BDQZGK16 |
| Currency | UK Pounds |
| Share Price | 11.25p |
| Change Today | -0.25p |
| % Change | -2.17 % |
| 52 Week High | 19.25 |
| 52 Week Low | 6.15 |
| Volume | 557,334 |
| Shares Issued | 125.16m |
| Market Cap | £14.08m |
| RiskGrade | 464 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:10 | 15,000 @ 11.11p |
| 15:59 | 50,000 @ 11.00p |
| 14:52 | 33,000 @ 11.09p |
| 13:55 | 7,454 @ 11.63p |
| 13:54 | 4,301 @ 11.63p |
| Chair | Simon Gordon Douglas |
| CEO | Adrian Kinkaid |
You are here: research